News

Featured News

View ASX Announcements here.

VIRALEZE™ Nasal Spray Approved in Malaysia (ASX Announcement)

Jun 5th, 2023

Starpharma today announces that it has achieved regulatory approval for its antiviral nasal spray product, VIRALEZE™, in Malaysia. The registration will allow Starpharma and its commercial partners to market and sell the product in Malaysia, a country with a population of over 33 million.

Quarterly Activities Report & Appendix 4C (ASX Announcement)

Apr 28th, 2023

Starpharma (ASX: SPL, OTCQX: SPHRY) today releases its Quarterly Activities Report and Appendix 4C for the period ended 31 March 2023 (Q3 FY23). Starpharma’s net operating cash outflows for the quarter were $4.9 million, and the closing cash balance as at 31 March 2023 was $38.9 million.

HER2-targeted DEP® SN-38 ADC outperforms in HER2+ human cancer model (ASX Announcement)

Apr 26th, 2023

Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that it has developed a HER2-targeted DEP^® SN-38 antibody-drug conjugate (ADC), which has shown significant anti-tumour activity in a HER2+ human ovarian cancer xenograft model, outperforming the approved ADC product, Enhertu^®[1].

AZD0466 active in small cell lung cancer patient models (ASX Announcement)

Apr 20th, 2023

Starpharma (ASX: SPL, OTCQX: SPHRY) today announces AZD0466 results from a preclinical study in small cell lung cancer (SCLC) patient-derived xenograft (PDX) models. Starpharma’s partner, AstraZeneca, presented these results overnight at the American Association for Cancer Research (AACR) Annual Meeting.

In the media

Commencement of CFO and Company Secretary (ASX Announcement)

Apr 3rd, 2023

Melbourne, Australia; 3 April 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce that, further to the announcement on 3 March 2023, Mr Justin Cahill commences in the role of Chief Financial Officer (CFO) and Company Secretary today.

Starpharma presents at ASX Small and Mid-Cap Conference (ASX Announcement)

Mar 22nd, 2023

Melbourne, Australia; 22 March 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) announces that Starpharma CEO Dr Jackie Fairley will present a brief overview of the Company at the ASX Small and Mid-Cap Conference today at 11:00am AEDT. The Conference showcases selected ASX-listed companies to Australian investors.

CFO and Company Secretary Appointment (ASX Announcement)

Mar 3rd, 2023

Melbourne, Australia; 3 March 2023: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Mr Justin Cahill as Chief Financial Officer (CFO) and Company Secretary, following an extensive executive search process. Justin will commence in the role in early April 2023.

Interim Report and Half-Year Financial Results - H1FY23 (ASX Announcement)

Feb 28th, 2023

Melbourne, Australia; 28 February 2023: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today releases its interim report and half-year financial results for the period ended 31 December 2022 (H1 FY23).

Sign up to receive news here